Stocks Health care YARW
NASDAQ · Health careYarrow Bioscience, Inc. (YARW)
Yarrow Bioscience, Inc. reported revenue of $570K in fiscal 2025, up 13.8% from a year earlier. It posted a net loss of $26.5M. In fiscal 2025 capital spending exceeded operating cash flow by $33.1M. At June 30, 2026 it held $22.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Yarrow Bioscience, Inc.
- Net worth
- Yarrow Bioscience, Inc. has a market value (market cap) of $41.3M at the latest share price, and shareholders' equity of $22.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $570K (+13.8% year on year), with a net loss of $26.5M.
- Cash flow
- In fiscal 2025 operations used $33.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Yarrow Bioscience, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Yarrow Bioscience, Inc. does
Yarrow Bioscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker YARW.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $570K | -$26.5M | -$0.62 | -$33.1M |
| 2024 | $501K | -$39.8M | -$0.93 | -$34.1M |
| 2023 | $424K | -$28.5M | -$2.78 | -$25.3M |
| 2022 | $477K | -$23.2M | -$7.28 | n/a |
| 2021 | $931K | -$73.3M | -$25.64 | -$56.4M |
| 2020 | $21M | -$255.6M | $7.88 | -$137.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where YARW ranks in Health care
Latest SEC filings
What Yarrow Bioscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 17, 2026Passive stake (5% or more) SCHEDULE 13G
- September 14, 2026Material agreement8-KYarrow Bioscience agreed to sell common stock in a public offering expected to raise approximately $161.8 million in net proceeds.
- September 10, 2026Other event 8-K
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Form POS AM filing POS AM
- August 13, 2026Quarterly results 8-K/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 41% to $97K versus the same quarter last year; diluted EPS -$3.51 versus -$6.73.
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Yarrow Bioscience, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 29, 2026 | RTW Fund Group GP, LLC10% owner | Other changeindirect | 133,290 | - |
| July 23, 2026 | Stuart IainCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | 15,405 | $13.8K |
| July 23, 2026 | Domzalski DavidPRESIDENT AND CEO, Director | Shares withheld for tax | 79,391 | $71.3K |
| July 23, 2026 | Harsch MutyaCHIEF LEGAL OFFICER AND GC | Shares withheld for tax | 22,516 | $20.2K |
| July 23, 2026 | Zeronda TylerCHIEF FINANCIAL OFFICER | Shares withheld for tax | 22,516 | $20.2K |
| June 30, 2026 | Stuart IainCHIEF SCIENTIFIC OFFICER | Shares withheld for tax | 2,370 | $1.5K |
| June 30, 2026 | Domzalski DavidPRESIDENT AND CEO, Director | Shares withheld for tax | 12,214 | $7.9K |
| June 30, 2026 | Harsch MutyaCHIEF LEGAL OFFICER AND GC | Shares withheld for tax | 3,464 | $2.3K |
Who owns YARW
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Logos Global Management LP13G, passive with 7 related filers | 10.7% | August 7, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 9.99% | August 7, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 9.99% | August 3, 2026 |
| RTW Fund Group GP, LLC13G, passive with 1 related filers | 9.99% | July 30, 2026 |
| venBio Global Strategic Fund V, L.P.13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 3 related filers | 9.97% | August 5, 2026 |
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 8.8% | August 14, 2026 |
| Raymond Debbane13G, passive with 7 related filers | 7.2% | September 17, 2026 |
| AI Biotechnology LLC13D, may seek influence with 3 related filers | 6.02% | July 29, 2026 |
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 6% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 45 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 4,000,000 | +2,000,000 |
| ADAR1 Capital Management, LLC | 2,950,000 | +1,886,101 |
| Lynx1 Capital Management LP | 1,628,700 | 0 |
| Shay Capital LLC | 1,456,651 | -153,591 |
| T3 Companies, LLC | 945,000 | 0 |
| Braidwell LP | 916,077 | 0 |
| KVP Capital Advisors, LP | 500,551 | 0 |
| Citadel Advisors LLC | 468,457 | -45,986 |
| Two Sigma Investments, LP | 438,818 | +12,406 |
| Ikarian Capital, LLC | 264,912 | 0 |
| Vanguard Capital Management LLC | 264,557 | 0 |
| Geode Capital Management, LLC | 258,203 | -64,508 |
| Vanguard Fiduciary Trust Co | 183,443 | 0 |
| Susquehanna International Group, Llp | 118,957 | +61,173 |
| Rangeley Capital, LLC | 113,064 | -5,000 |
| XTX Topco Ltd | 78,721 | -79,675 |
| Superstring Capital Management LP | 61,269 | new |
| UBS Group AG | 58,597 | -121,187 |
| BlackRock, Inc. | 44,405 | 0 |
| Northern Trust Corp | 43,677 | +20,567 |
Insiders
5 insiders reported holding 880,261 shares in total, about $13.6M at the last price.
| Holder | Shares |
|---|---|
| Domzalski DavidPRESIDENT AND CEO, Director | 347,174 |
| RTW Fund Group GP, LLC10% owner | 266,307266,307 held indirectly |
| Stuart IainCHIEF SCIENTIFIC OFFICER | 95,944 |
| Harsch MutyaCHIEF LEGAL OFFICER AND GC | 95,918 |
| Zeronda TylerCHIEF FINANCIAL OFFICER | 74,918 |
Questions about YARW
What does Yarrow Bioscience, Inc. do?
Yarrow Bioscience, Inc. is a company in the Health care sector, listed on NASDAQ as YARW. Its shares trade on NASDAQ under the ticker YARW.
What is Yarrow Bioscience, Inc.'s net worth?
Yarrow Bioscience, Inc. has a market value (market cap) of $41.3M at the latest share price, and shareholders' equity of $22.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Yarrow Bioscience, Inc. profitable?
No. In fiscal 2025 it reported a net loss of $26.5M on revenue of $570K.
How much revenue does Yarrow Bioscience, Inc. make?
In fiscal 2025 Yarrow Bioscience, Inc. reported revenue of $570K. That is 13.8% more than a year earlier.
When did Yarrow Bioscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from September 17, 2026.
When is Yarrow Bioscience, Inc.'s next earnings report?
Yarrow Bioscience, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare YARW with
Follow YARW
Get an email when Yarrow Bioscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Yarrow Bioscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.